MX2018009820A - Uso de cart19 para eliminar celulas b normales para inducir tolerancia. - Google Patents

Uso de cart19 para eliminar celulas b normales para inducir tolerancia.

Info

Publication number
MX2018009820A
MX2018009820A MX2018009820A MX2018009820A MX2018009820A MX 2018009820 A MX2018009820 A MX 2018009820A MX 2018009820 A MX2018009820 A MX 2018009820A MX 2018009820 A MX2018009820 A MX 2018009820A MX 2018009820 A MX2018009820 A MX 2018009820A
Authority
MX
Mexico
Prior art keywords
cart19
cells
induce tolerance
deplete normal
present
Prior art date
Application number
MX2018009820A
Other languages
English (en)
Inventor
Carl H June
Bruce L Levine
Michael D Kalos
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2018009820A publication Critical patent/MX2018009820A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona composiciones y métodos para inducir tolerancia en un humano. La presente invención incluye administrar una célula T genéticamente modificada que expresa un CAR, en donde el CAR comprende un dominio de enlace de antígeno, un dominio de transmembrana, una región de señalización coestimuladora, y un dominio de señalización zeta CD3.
MX2018009820A 2012-07-13 2015-01-09 Uso de cart19 para eliminar celulas b normales para inducir tolerancia. MX2018009820A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261671508P 2012-07-13 2012-07-13

Publications (1)

Publication Number Publication Date
MX2018009820A true MX2018009820A (es) 2022-08-24

Family

ID=49916701

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015000433A MX382772B (es) 2012-07-13 2013-07-12 Composición para usarse para prevenir o retardar el rechazo de trasplante de un tejido u órgano trasplantado en un sujeto.
MX2018009820A MX2018009820A (es) 2012-07-13 2015-01-09 Uso de cart19 para eliminar celulas b normales para inducir tolerancia.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015000433A MX382772B (es) 2012-07-13 2013-07-12 Composición para usarse para prevenir o retardar el rechazo de trasplante de un tejido u órgano trasplantado en un sujeto.

Country Status (13)

Country Link
US (3) US20150290244A1 (es)
EP (1) EP2872184B1 (es)
JP (5) JP2015523386A (es)
KR (1) KR102216083B1 (es)
CN (2) CN120393001A (es)
AU (3) AU2013289984B2 (es)
BR (1) BR112015000657B1 (es)
CA (1) CA2876734A1 (es)
EA (2) EA034644B1 (es)
ES (1) ES2835232T3 (es)
IN (1) IN2015DN00139A (es)
MX (2) MX382772B (es)
WO (1) WO2014012001A2 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
IN2015DN00139A (es) * 2012-07-13 2015-06-12 Univ Pennsylvania
TW201446794A (zh) 2013-02-20 2014-12-16 Novartis Ag 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
HUE046961T2 (hu) 2013-02-20 2020-04-28 Univ Pennsylvania Rák kezelése humanizált EGFRVIII elleni kiméra antigénreceptor alkalmazásával
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
BR112016013187A2 (pt) 2013-12-19 2017-09-26 Novartis Ag receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP3097117B1 (en) 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
MX395149B (es) 2014-04-07 2025-03-24 Novartis Ag Terapias de combinación que comprenden un receptor quimérico de antígeno cd19 para el cáncer.
BR112016024579A2 (pt) 2014-04-23 2017-10-10 Juno Therapeutics Inc métodos para isolamento, cultura e engenharia genética de populações de célula imune para terapia adotiva
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
MX2017001011A (es) 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
AR101829A1 (es) 2014-07-21 2017-01-18 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
TW202140557A (zh) 2014-08-19 2021-11-01 瑞士商諾華公司 使用cd123嵌合抗原受體治療癌症
WO2016028879A1 (en) * 2014-08-19 2016-02-25 The Children's Hospital Of Philadelphia Compositions and methods for modulating immune response
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
KR20210149228A (ko) 2014-09-17 2021-12-08 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
CA2963935A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
EP4036109A3 (en) * 2014-12-29 2022-10-12 Novartis AG Methods of making chimeric antigen receptor-expressing cells
WO2016115482A1 (en) 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN119925616A (zh) 2015-04-08 2025-05-06 诺华股份有限公司 Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法
CA2982996A1 (en) 2015-04-17 2016-10-20 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN114099712A (zh) 2015-05-06 2022-03-01 斯尼普技术有限公司 改变微生物种群和改善微生物群
TWI859112B (zh) 2015-07-21 2024-10-21 瑞士商諾華公司 改良免疫細胞之功效及擴展之方法
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
CN108780084B (zh) 2015-09-03 2022-07-22 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
HK1258726A1 (zh) * 2015-09-28 2019-11-15 Regents Of The University Of Minnesota 嵌合抗原受体(car)t细胞作为获得自体免疫和同种免疫的治疗性干预
CN114470193B (zh) * 2015-10-13 2024-08-30 优瑞科生物技术公司 对人类cd19具有专一性的抗体药剂和其用途
HK1257295A1 (zh) 2015-12-04 2019-10-18 Novartis Ag 用於免疫肿瘤学的组合物和方法
EP3393504B1 (en) 2015-12-22 2025-09-24 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
JP7497955B6 (ja) * 2016-04-15 2024-07-01 ノバルティス アーゲー 選択的タンパク質発現のための組成物および方法
EP3443076A4 (en) * 2016-04-15 2020-04-15 The Trustees of the University of Pennsylvania COMPOSITIONS AND METHODS FOR CHIMERAL ALLOANTigen RECEPTOR T CELLS
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
KR20230107408A (ko) * 2016-07-29 2023-07-14 주노 쎄러퓨티크스 인코퍼레이티드 항-cd19 항체에 대한 항-이디오타입 항체
CN110225927B (zh) 2016-10-07 2024-01-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
AU2017368248A1 (en) * 2016-11-30 2019-06-06 Intrexon Corporation Steroid administration and immunotherapy
EP3346001A1 (en) * 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
CN110832075A (zh) 2017-03-22 2020-02-21 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
US11999802B2 (en) 2017-10-18 2024-06-04 Novartis Ag Compositions and methods for selective protein degradation
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
AU2019311077B2 (en) * 2018-07-23 2025-05-29 Heidelberg Pharma Research Gmbh Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
MX2021002265A (es) 2018-08-31 2021-05-27 Univ Yale Composiciones y métodos para aumentar la edición genética basada en oligonucleótidos de donador.
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
AU2020336992A1 (en) 2019-08-30 2022-04-14 Yale University Compositions and methods for delivery of nucleic acids to cells
CN114761037A (zh) 2019-11-26 2022-07-15 诺华股份有限公司 结合bcma和cd19的嵌合抗原受体及其用途
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors cd19 and cd22 and their uses
US20230055186A1 (en) * 2019-12-27 2023-02-23 Zhaotai Immugene Biomedicine (Hong Kong) Limited Engineered immune killer cell, preparation method therefor and use thereof
EP4087601A2 (en) * 2020-01-10 2022-11-16 Coimmune, Inc. Methods of treating tumors
AU2021331785A1 (en) 2020-08-31 2023-03-30 Gennao Bio, Inc. Compositions and methods for delivery of nucleic acids to cells
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
AU2023361162A1 (en) 2022-10-11 2025-05-29 Yale University Compositions and methods of using cell-penetrating antibodies
WO2024119101A1 (en) 2022-12-01 2024-06-06 Yale University Stimuli-responsive traceless engineering platform for intracellular payload delivery
EP4574838A1 (en) 2023-12-21 2025-06-25 Vilnius University Chimeric antigen receptor (car) with enhanced recruitment of signaling partners

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2587407A1 (en) * 2004-11-17 2006-05-26 Angiogen Pharmaceuticals Pty. Ltd. A method of modulating b cell functioning
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
EP2403532A4 (en) * 2009-03-06 2012-12-05 Medimmune Llc HUMANIZED ANTI-CD19 ANTIBODY FORMULATIONS
WO2011059836A2 (en) * 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
WO2011097477A1 (en) * 2010-02-04 2011-08-11 The Trustees Of The University Of Pennsylvania Icos critically regulates the expansion and function of inflammatory human th17 cells
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9233125B2 (en) * 2010-12-14 2016-01-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
IN2015DN00139A (es) * 2012-07-13 2015-06-12 Univ Pennsylvania

Also Published As

Publication number Publication date
ES2835232T3 (es) 2021-06-22
US20150290244A1 (en) 2015-10-15
AU2013289984B2 (en) 2018-03-08
JP2015523386A (ja) 2015-08-13
AU2018203756B2 (en) 2019-10-24
CA2876734A1 (en) 2014-01-16
BR112015000657A8 (pt) 2018-01-16
BR112015000657B1 (pt) 2023-12-05
WO2014012001A2 (en) 2014-01-16
JP2025129358A (ja) 2025-09-04
AU2018203756A1 (en) 2018-06-21
WO2014012001A3 (en) 2015-04-23
US20180271907A1 (en) 2018-09-27
BR112015000657A2 (pt) 2017-06-27
EA201992742A2 (ru) 2020-09-30
EP2872184A4 (en) 2016-03-30
AU2020200315A1 (en) 2020-02-06
MX2015000433A (es) 2016-04-28
KR102216083B1 (ko) 2021-02-17
EA201590209A1 (ru) 2015-08-31
EP2872184B1 (en) 2020-09-16
CN104884095A (zh) 2015-09-02
AU2020200315B2 (en) 2021-11-04
EA201992742A3 (ru) 2020-12-30
US20240261328A1 (en) 2024-08-08
MX382772B (es) 2025-03-11
CN120393001A (zh) 2025-08-01
IN2015DN00139A (es) 2015-06-12
JP2022173331A (ja) 2022-11-18
AU2013289984A1 (en) 2015-01-22
EA034644B1 (ru) 2020-03-02
JP2018135363A (ja) 2018-08-30
KR20150030750A (ko) 2015-03-20
EP2872184A2 (en) 2015-05-20
JP2020158541A (ja) 2020-10-01

Similar Documents

Publication Publication Date Title
MX2018009820A (es) Uso de cart19 para eliminar celulas b normales para inducir tolerancia.
NI201300051A (es) Uso de células t de receptor modificado antígeno quiméricas para tratar el cáncer.
IN2014DN07414A (es)
MX2017003645A (es) Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
MX2013012593A (es) Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
MX2015000438A (es) Manejo de toxicidad para actividad antitumoral de cars.
MX2014010183A (es) Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
IN2014DN06522A (es)
MX2020001450A (es) Composiciones para reducir la inmunosupresion por celulas de tumor.
BR112013006718A2 (pt) epítopos de células t e receptores de células t antígeno-específicos
MX390943B (es) Receptores de antígeno quimérico cd33 y usos de los mismos.
UY34456A (es) Anticuerpos anti-il-36r
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
NI201400061A (es) Anticuerpos anti - phf - tau y sus usos
TR201818988T4 (tr) Multipl skleroz semptomlarını hafifletmeye yönelik apoaequorin içeren bileşimlere dayalı yöntemler.
CU20130079A7 (es) Uso de células t modificadas por receptor de antígeno quimérico para tratar cáncer
TR201907505T4 (tr) Anti-DR5 ailesi antikorları, bispesifik veya çok değerlikli anti-DR5 ailesi antikorları ve bunların kullanım yöntemleri.